

TRENDS IN ANTIMICROBIAL RESISTANCE PATTERN AND AN OVERVIEW ON ITS CONTRIBUTING FACTORS & PREVENTIVE MEASURES

Maheshwari P¹, Immanuel Jebastine M², Aakash.R², Dharshne P.T², Aswin Prathap S², Deepak Raj S², Shanmugasundaram P³

¹Associate Professor, Department of Pharmacy Practice, School of pharmaceutical sciences, Vel's institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India.

²Department of Pharmacy Practice, School of pharmaceutical sciences, Vel's institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India.

³Director, School of pharmaceutical sciences, Vel's institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India.

Corresponding Author Email: aakashdr2001@gmail.com

DOI: 10.47750/pnr.2023.14.02.386

Abstract

The World Health Organization has highlighted antimicrobial resistance as a major concern to community health, hence it is crucial to understand the types of primarily isolated pathogens from various biological samples such as blood, urine, sputum, pus, stool, ear discharge & etc, and their corresponding antimicrobial resistance pattern in a particular region for the better clinical services, among the isolated gram-negative & gram-positive pathogens, such as *Escherichia coli*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Klebsiella*, *Enterobacteriaceae*, *salmonella*, *shigella*, *proteus* species and *Staphylococcus aureus* & *streptococcus* species respectively were involved in the development of numerous infectious diseases, in which these above mentioned pathogens were highly resistance to majority of the conventional antibiotics, especially to 3rd generation cephalosporins, while Aminoglycosides and Carbapenem class of antibiotics was found to be highly effective towards most of the pathogens specified. Inappropriate antibiotics use, poor infection control, poor hygiene, self-medication and prolonged use of antibiotics are considered to be the significant driving factors for emergence of antimicrobial resistance (AMR). It is necessary to stop antibiotics misuse and OTC antibiotics to prevent AMR. Rational use of antibiotics and surveillance plays a major role in AMR prevention. By following recommended practice guidelines and infection control protocols AMR can be managed. The key factors associated with AMR treatment is reduction of antimicrobial use and prevention of AMR emergence. This review provides a detailed study on the antimicrobial resistance pattern of various pathogens & prevention, treatment and factors associated with AMR.

KEY WORDS: Antimicrobial resistance, Microbiological culture, antimicrobial stewardship, Gram-negative species, Infection prevention & control.

INTRODUCTION:

Antimicrobial resistance is a condition whereby, previously susceptible microbes develop resistance to antimicrobial treatments, in which a unique adaptive push to create a retaliation response to an antibiotic or group of antibiotics led to the fundamental cause of resistance^[1]. Antimicrobial resistance has attained a tipping phase and has become a world concern to population health on a global scale. The World Health Organization

(WHO) recently identified antimicrobial resistance as a global health concern and advised various nations to develop a strategy to address the issue [2]. Microbial strains from clinical samples are evaluated for their sensitivity to antimicrobials in order to identify potential antibiotic resistance in prevalent microorganisms and confirm their sensitivity to the recommended antibiotics for a given infection. Since sensitivity might differ significantly among the organism, they are carried out to assess which drug will best manage the infections caused by bacterial species in vivo [3]. Numerous pathological disorders, including urinary tract infection, bacteremia, pneumonia, healthcare associated infections, opportunistic & other infections are brought on by gram-negative bacteria in comparison with gram-positive species [4][6]. Bloodstream infections are identified by the existence of active pathogenic microorganisms, which cause an immune process and frequently change medical, biochemical, and physiological variables and are the main source of morbidity and mortality in individuals of all ages, especially in patients with impaired immune systems [5][7]. Urinary tract infection (UTI) refers to the bacterial invasion and inflammation of parts associated with urinary system such as pyelonephritis, cystitis and urethritis, which are the major types of UTI's that can be characterised as complicated & uncomplicated UTI's [10]. To a Minimum UTI affects greater than 50% of women at a certain point over their lifetime & most will experience relapses [9] and this may be due to several biological and anatomical aspects of humans, such as the fact that women's urethras are shorter than men's, partial bladder emptying and the vesicoureteral reflux commonly seen in pregnant women enhance the likelihood of developing a UTI [8]. Acute & chronic bronchitis, pneumonia are the most prevalent lower respiratory tract infections (LRTIs) and are linked to severe morbidity, mortality, and enormous medical expenditures [12] and are accompanied with lung abscess, pleural effusion preceded by respiratory distress, sepsis and multi-organ failure [13]. Injury, cell waste, and dead tissues are created as the outcome of pyogenic organisms infecting human skin and soft tissue during or post trauma, skin burns, and surgical treatments [16] usually marked by many localised inflammations, typically with pus development as a result of immune responses, which are sent to the site of infection as part of the body's defence strategy to combat pyogenic microbes [15], while orthopaedic patients frequently experience skin infections in comparison to normal population, which can be brought on by both gram-positive and gram-negative bacteria [14]. According to the World Health Organization (WHO), diarrhoea is described as passing three or more watery or loose stools per day, with a rise in water composition, quantity, and regularity of bowel movements and also associated with other symptoms like nausea & vomiting, fever and cramping [18], however it is primary contributor to morbidity and mortality especially in children and teenage adulthood notably in places where resources are scarce and where hygiene standards are not properly observed [17]. Chronic suppurative otitis media (CSOM) is described as a middle ear inflammation that remains for more than six weeks with a ruptured tympanic membrane discharging effluent and which frequently coexists with cholesteatoma [19] & are primarily triggered by microbial infection which are generally associated with hearing impairment and intracranial consequences [20]. Inappropriate use of broad-spectrum antibiotics leads to development of Multidrug resistant (MDR) organisms [32]. Antimicrobial resistance (AMR) development can be provoked by antibiotics misuse [25]. Overuse/misuse of antibiotics, poor hygiene, self-medication are the major driving factors for the development and spread of AMR [29][31][42].

ANTIMICROBIAL RESISTANCE PATTERN OF BACTERIAL ISOLATES FROM CULTURES:

a) *Blood culture:*

According to Alka Hasani et al. [5] Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Coagulase negative Staphylococcus, Klebsiella pneumonia, Enterobacter species were prominently identified microorganisms responsible for blood stream infections, in which these organisms are majorly resistant against gentamycin, ofloxacin. Cefotaxime, ceftazidime, ceftriaxone and co-trimoxazole in an increasing manner and moderately resistant against fluoroquinolones, and majorly sensitive towards amikacin and imipenem.

According to the study conducted by Tamanna Zerín et al. [6] The most prevalent pathogen was E. coli, preceded by Staphylococcus aureus, Klebsiella pneumoniae, Staphylococcus epidermidis, Salmonella species,

Streptococcus viridans & *Pseudomonas aeruginosa*, in which the resistance pattern of cloxacillin for *Streptococcus viridans*, gentamycin for *Staphylococcus epidermidis*, azithromycin and linezolid for *Staphylococcus aureus*, ciprofloxacin & co-trimoxazole for *Salmonella* species, ceftriaxone & moxifloxacin for *Klebsiella pneumoniae*, aztreonam & colistin for *Pseudomonas aeruginosa*, ceftriaxone, cefuroxime for *E.coli* were discovered. Whereas, all the identified bacteria were sensitive towards cefepime & meropenem, while imipenem and nitrofurantoin are effective towards gram-negative & gram-positive microbes respectively.

Similarly in a study initiated by John Gameli Deku et al. [7] Demonstrated that the development or synthesis of the extended-spectrum beta-lactamase (ESBL) enzyme is linked to the rising resistance to second- and third-generation cephalosporins, notably cefuroxime and cefotaxime.

b) Urine culture:

According to Syed Suhail Ahmed et al. [8] Gram-negative organisms such as *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Enterococcus faecalis* and *Enterobacter cloacae* are the prominent microbes responsible for developing urinary tract infections, which possess a broad range of resistance to ampicillin, piperacillin, amoxicillin-clavulanic, nitrofurantoin, co-trimoxazole & cefuroxime, also the intermediate range of resistance to ciprofloxacin, ceftiofloxacin, norfloxacin, piperacillin-tazobactam and 3rd generation cephalosporins, whereas these microbes are highly sensitive to cefepime, tobramycin, gentamycin, amikacin and meropenem.

A study by Jamaan Al-Zahrani et al. [9] *Escherichia coli*, *Klebsiella*, *Enterobacter*, *proteus* & *pseudomonas* species are the unique pathogens identified from the patient urine cultures known to cause uncomplicated cystitis, in which these microbes show an ascending spectrum of resistance to aztreonam, nitrofurantoin, piperacillin, co-trimoxazole, cephalothin and ampicillin with a sensitivity sequence to ciprofloxacin and levofloxacin.

Similar results have been proposed in the study conducted by Harshkumar B. Patel et al. [10] & according to this study, it may be advised to use nitrofurantoin as an empiric antibiotic therapy in place of cotrimoxazole and ciprofloxacin for uncomplicated cystitis. Aminoglycosides and carbapenems are recommended over fluoroquinolones and cephalosporins for treating mild to severe pyelonephritis.

c) Sputum culture:

According to Zaharaddin Muhammad Kalgo et al. [11] *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Aeromonas hydrophila* are the majorly detected bacterial species of Lower respiratory tract infections with a greater sensitivity profile descending from gentamycin, ciprofloxacin, azithromycin, co-trimoxazole & piperacillin. Whereas, *Staphylococcus aureus*, *Klebsiella* species and *Escherichia coli* exhibited a broad scope & intermediate scope of resistance especially for 3rd generation cephalosporins respectively, while *Pseudomonas aeruginosa* & *Aeromonas hydrophila* exhibited resistance to nearly all of the examined antibacterial agents.

According to Biagio Santella et al. [12] *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Staphylococcus aureus* and *Acinetobacter baumannii* are the principal microbes responsible for lower respiratory tract infections (LRTI's) and illustrates extended level of sensitivity to colistin, vancomycin & linezolid. Whereas these microbes exhibited broad scope of resistance to penicillin, fluoroquinolones and cephalosporins type of agents with an intermediate level of sensitivity to ertapenem, gentamycin, tetracycline and co-trimoxazole.

Likewise in the study initiated by Sadia Batool et al. [13] stated that *Streptococcus pneumoniae*, *Staphylococcus aureus* and *Haemophilus influenzae* are the importantly identified microbes responsible for LRTI's. *Streptococcus pneumoniae* showed greater sensitivity for macrolide antibiotics, *Haemophilus influenzae* and *Staphylococcus aureus* showed high sensitivity for ceftriaxone, levofloxacin. Amoxicillin-sulbactam, ciprofloxacin, ceftazidime, azithromycin and amikacin respectively with a poor scope of sensitivity to ampicillin & trimethoprim-sulfamethoxazole.

d) Pus culture:

According to Lee Kapalisya Mwakalinga et al. ^[14] *Staphylococcus aureus* and *Pseudomonas aeruginosa*, *Escherichia coli* are the most typically identified gram positive & gram-negative bacterial species respectively, and shows greater level of sensitivity against amoxicillin-clavulanic acid, clindamycin, amikacin, ciprofloxacin & gentamycin. Whereas ceftriaxone and ampicillin resistance are common in gram-negative bacteria's and erythromycin, vancomycin & trimethoprim-sulfamethoxazole resistance in common among gram-positive organism.

According to Dayavanti Kumari et al. ^[15] *Staphylococcus aureus*, Coagulase negative *Staphylococcus*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* & *Escherichia coli* are the majorly identified bacterial species, in which *Staphylococcus aureus*, *Enterococcus faecalis* & Coagulase negative *Staphylococcus* exhibited extremely high level of susceptibility to vancomycin & linezolid, and *Escherichia coli*, *Klebsiella pneumoniae* & *Pseudomonas aeruginosa* exhibited the same to tigecycline & colistin. Whereas, other antibacterial agents such as, tetracycline, gentamycin, teicoplanin, clindamycin, erythromycin, ciprofloxacin, cotrimoxazole & meropenem were also found to be considerably effective.

In the study conducted by Krishna Kumar Patel et al. ^[16] *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Citrobacter* species, *Acinobacter baumannii*, *Proteus mirabilis* & *Streptococcus* species, Gram-negative bacteria predominated among the isolates from wound samples in contrast to Gram-positive bacteria. High level of resistance to cephalosporins, amoxicillin/clavulanic acid and azithromycin, ciprofloxacin, ampicillin, amoxicillin/clavulanic acid was exhibited by *E. coli* and *S. aureus* respectively. While meropenem, linezolid, imipenem, vancomycin was effective against *S. aureus*. *P. aeruginosa*, *P. mirabilis* & *Streptococcus* species showed little resistance and were sensitive to the majority of anti-bacterial agents.

e) Stool culture:

In the study conducted by A. Samie et al. ^[17] proposed that *Campylobacter* species, *Aeromonas* species, and *Salmonella* species appeared as the most typically identified bacterial species. These pathogenic agents were found to be considerably attributed with diarrhoea, with expanding resistance to antibacterial drugs such as erythromycin in case of *Campylobacter* species, tetracycline in case of *Shigella*, and ampicillin in case of *Salmonella* species. The sensitivity trend of diarrhoea-causing microbial species, which include *Yersinia enterocolitica*, *Shigella*, *E. coli*, and *Salmonella* were highly sensitive to polymyxin B, norfloxacin, gentamicin and nalidixic acid. It was also discovered that ampicillin was ineffective towards the majority of the organisms tested, whereas gentamicin was successfully effective towards the majority of the species examined.

According to Achenef Melaku Beyene et al. ^[18] *shigella* species, *salmonella enterica*, *E. coli* and *campylobacter* species appeared as the most typically identified gram negative intestinal bacterial species which serves crucial role in the onset or extent of diarrhoea. Among these pathogenic agents *shigella* and *salmonella* species shows greater extent of resistance to ampicillin & amoxicillin, with a lower extent of resistance to ciprofloxacin & ceftriaxone. Whereas *E. coli* and *campylobacter* species exhibited greater level of resistance towards tetracycline, trimethoprim-sulphamethoxazole & ampicillin. On the other hand, erythromycin and chloramphenicol were ineffective towards *campylobacter* species.

f) Ear discharge:

According to Rahel Molla et al. ^[19] *P. mirabilis* and *S. aureus* emerged as the most frequently found bacterial species. *P. vulgaris*, *Pseudomonas*, *Providencia* species, *Citrobacter* species, *Klebsiella* species, *Enterobacter* species have also been identified. This study also sheds light on the resistance pattern of identified bacteria from ear infections and revealed that chloramphenicol, nalidixic acid, ciprofloxacin, gentamicin, and norfloxacin are active towards Gram-negative bacterial species, while cefixime, cefuroxime, and cefepime have a considerable spectrum of sensitivity against Gram-negative bacteria. Amoxicillin-clavulanic acid, gentamicin, chloramphenicol, clarithromycin, and tobramycin, on the other hand, were reasonably effective towards Gram-positive bacteria.

In the study conducted by Jianghong Xu et al. [20] stated that *Staphylococcus aureus* and *P. aeruginosa* emerged as the most frequently found bacterial species. Cephalosporins and fluoroquinolones are the most commonly given oral antibiotics for CSOM in China. The *Staphylococcus aureus* species discovered in this investigation were significantly resistant to penicillin and erythromycin. Likewise, vancomycin, gentamicin, rifampicin, moxifloxacin, sulfamethoxazole and trimethoprim were extremely effective against *S. aureus* species. Also, Piperacillin, piperacillin/tazobactam, and meropenem were all effective against isolated *Pseudomonas aeruginosa*, whereas, Levofloxacin, ciprofloxacin, and ceftriaxone are all extremely resistant to *Pseudomonas aeruginosa* cultures.

IMPACT OF EMPIRICAL THERAPY IN THE DEVELOPMENT OF ANTIMICROBIAL RESISTANCE:

Antimicrobial resistance is the major public health concern. The major drug resistance is identified mostly among MDR *Pseudomonas aeruginosa*, Methicillin resistant *Staphylococcus aureus* (MRSA), Vancomycin resistant enterococci (VRE) and Enterobacteriaceae producing extended spectrum beta lactamases (ESBL's) [21]. All these resistant bacteria are mostly resistant to carbapenems and quinolones [22]. Carbapenems are the one and only drug in beta lactamases which maintains its potential activity against MDR Enterobacteriaceae producing ESBL's. It is also indicated by clinical data's that carbapenems are the only drug of choice for the management of chronic infection induced by similar strains [21].

In a study conducted by Department of Infectious Disease, University of Verona in government hospital of Trieste, Italy shows that by reducing the use of piperacillin-tazobactam, they obtained decreased resistance to *Aeruginosa* by 57% to this drug, at the same time they also noted increased resistance to the drug imipenem. In hospital acquired pneumonia; as an empirical therapy imipenem was replaced with piperacillin-tazobactam [22]. The use of high dose beta lactam antibiotics and macrolides was suggested by the American Thoracic Society and Infectious Disease society of America for the empiric treatment of community acquired pneumonia. This empirical treatment shows less resistance against *Streptococcus pneumoniae* [28].

It is stated that uncomplicated urinary tract infections (UTI's) should be managed empirically with the use of Trimethoprim and Sulfamethoxazole by Infectious Disease Society of America Guidelines. If the community resistance exceeds 10-20% among uropathogens, then it must be treated with fluoroquinolones [23]. Fusidic acid acts mainly against gram positive bacteria with a potential invitro activity against *S. aureus*. Its resistance is very low due to its advanced penetration in damaged skin [24]. In therapy of infectious wounds, mupirocin acts as a narrow spectrum anti-staphylococcal topical drug, prescribed empirically due to its low resistance [24].

Development of antibacterial resistance can be provoked by antibiotics misuse. Follow appropriate antimicrobial use in order to prevent the development of AMR and to improve clinical benefit [25]. Unpropitious mortality rate can occur in co-morbid patients due to inappropriate empiric use of antimicrobials [26]. Without any indication of bacterial infection, fluoroquinolones and Piperacillin/tazobactam were repeatedly prescribed in Covid-19 patients as an empirical therapy. Inappropriate use of broad-spectrum antibiotics leads to development of multidrug resistant organisms [32].

FACTORS ASSOCIATED WITH ANTIMICROBIAL RESISTANCE

Factors promoting the spread of AMR-bacteria are:

- Inappropriate use of antibiotics in clinical practice [29] [31].
- Overcrowding in hospitals
- Infection control failure
- Poor hand / personal hygiene
- Self-medication [29] [31].

- Misuse of antibiotics/antimicrobials [29] [38] [42] [43] [44] [45].
- In *E. coli*, *K. pneumoniae* and *P. aeruginosa*; the risk factor for the ciprofloxacin resistant bacteria is the use of fluoroquinolones [30].
- Improper prescribing patterns [38] [42].
- Insufficient new novel antibiotics [38].
- Healthcare facilities and Pharma industries releases antibiotics and its residues into the environment that results in the frequent development and spread of antimicrobial resistant organisms in environment [27] [31] [42].
- Multidrug resistant gram-negative bacteria, MRSA, VRE are primarily transmitted by direct or indirect contact from one person to another [29].
- Long term hospitalization / use of antibiotics [29] [42].
- Frequent use of broad-spectrum antibiotics (e.g., cephalosporin, fluoroquinolone) [29] [31].
- Urinary catheterization, abundant antibiotic use, humidifiers and nebuliser contamination are the major driving factors for the spread of gram-negative resistant bacteria [29] [30].
- Overuse of Penicillin, overcrowding, tracheostomies are the factors for the spread of penicillin resistant pneumococci (PRP) [29].
- Delayed diagnosis, poor ventilation, poor isolation facilities are the driving factors for the transmission of multidrug resistant *Mycobacterium tuberculosis* (MDR-Tb) [29].

PREVENTIVE STRATEGIES TO COMBAT ANTIMICROBIAL RESISTANCE:

The worldwide difficulty of antimicrobial resistance is increasing. The strategies to combat AMR are;

- Prevention of unnecessary overuse or misuse of antibiotics [34] [35] [38].
- Antibiotics should be prescribed rationally [34] [43] [45] [41].
- Prevention and control of infection [33] [35] [38] [41].
- Cessation of OTC antibiotics [34].
- Maintain hand and personal hygiene [33] [34] [35] [36].
- Surveillance of antimicrobial resistance [34] [37].
- Follow guidelines for standard treatment [34].
- Initiation of advanced AMR programmes [33] [34].
- Since it is important to reduce the emergence of antimicrobial resistance during treatment; it is essential to stop the antibiotics that motivates the transfer of genes [34].
- Evaluate the impact of various driving factors of antibiotics resistance in population [35].
- Before hospital admission always pre-screen for any carrier status [36].
- Hospital rooms must be disinfected regularly [36].
- A low rate of antimicrobial resistance will be achieved by reducing the antibiotics consumption [45] [36].
- Antimicrobial prescribing should be monitored carefully [36].

TREATMENT RECOMMENDATIONS TO COMBAT ANTIMICRIBIAL RESISTANCE:

Misuse of antibiotics has resulted in emergence of various antibiotics resistance and formation of superbugs. In order to combat AMR, practice guidelines implementation would result in increased appropriateness of AMR

management and improved therapy success; but AMR cannot be controlled if additional measures aren't reinforced. In AMR treatment; it is important to prevent the spreading of resistant bacteria. In hospital, practice guidelines for precaution of isolation were introduced by centres for disease control and prevention (CDC) in the period of 1996 in which it indicates hand hygiene as a major essential measure to decrease the probability of spreading organisms from person to person ^{[37][39]}.

- For the surveillance of antimicrobial resistance and antimicrobial use; it is mandatory to develop an effective system^{[37][40]}.
- In order to control the cross-transmitting of resistant microbe; it is essential to reinforce appropriate infection control measure^{[37][39]}.
- Inappropriate use of antibiotics should be stopped, if not, it would result in multi-drug resistant bacteria (MDR-Bacteria) and superbugs^{[37][39]}.

For the management of AMR; various suggestions were listed as follows:

1. Suggestion for clinicians in managing AMR:

- a) For prescribing antibiotics; always follow recommended guidelines strictly^[38].
- b) In order to prevent infection, infection control guidelines and protocols are to be practiced^[38].
- c) The patient or their care taker must be counselled about the antibiotic use / consequence of antibiotic misuse like developing of AMR or allergic reaction^{[38][44]}.

2. Suggestion for patient / care taker:

- a) Patient / caretaker must be notified about AMR.
- b) Patient / caretaker must be accepting counselling from physician about
 - i. Treatment plan
 - ii. Duration of therapy
 - iii. Contraindication
 - iv. Indication
 - v. ADR of drug.
- c) Proper personal / hand hygiene must be practiced.
- d) Avoid public contact if he / she is sick.
- e) Periodic vaccination must be obtained^[38].

3. Suggestion for health care organizations:

- a) In order to identify the source of misuse, prescribing patters in clinics, community hospitals and nursing home are to be monitored regularly^[38].
- b) Organize educational programmes for physicians and public about antibiotics use and consequences of its misuse^[38].
- c) For diagnosing and managing infections disease; establish an effective practice guideline^[38].
- d) Support the researchers in developing advanced technologies and drugs to promote optimal antimicrobial use^{[38][39]}.
- e) Prevent antibiotics resistance and develop new novel antibiotics^{[38][43]}.
- f) AMR surveillance is an important aspect in AMR treatment which provides adequate information to develop,
 - i. Therapy guidelines for monitoring AMR
 - ii. Antibiotics formularies
 - iii. Antibiotics stewardship programmes
 - iv. Public health intervention
 - v. Infection control strategies
 - vi. Novel antibiotics and vaccines^{[40][44]}.
- g) To treat resistance microbes; it is essential to develop new antimicrobial therapies^[44].

h) The key factors in reducing the emergence of AMR are reduced antimicrobial use and prevention of development of antimicrobial resistance^[44].

CONCLUSION:

From the above retrieved study, we come to know about the predominance of numerous gram-negative & gram-positive microorganisms and their pattern of antimicrobial resistance, which are involved in the development of various infectious diseases associated with blood, urine, sputum, pus, stool & ear discharge, which aids in the decision of empirical treatment. In order to prevent AMR and to combat AMR it is important to prevent overuse / misuse of antibiotics. Implementation of rational use of antibiotics plays a major role in preventing antimicrobial resistance. In AMR treatment it is essential to prevent the spread of resistant bacteria. To combat antimicrobial resistance, antibiotics must be prescribed according to recommended guidelines and follow infection control protocols. However, the antimicrobial resistance monitoring framework must be built to comprehend the pattern of antibiotic resistance across harmful bacteria and to prepare and carry out preventive measures including adequate prevention and control of contagious diseases and antimicrobial stewardship schemes. Although even more research is required to fully comprehend the pattern of antimicrobial resistance from multiple biological samples for further conclusion.

REFERENCES:

1. Abebe M, Tadesse S, Meseret G, Derbie A. Type of bacterial isolates and antimicrobial resistance profile from different clinical samples at a Referral Hospital, Northwest Ethiopia: five years data analysis. *BMC research notes*. 2019 Dec;12(1):1-6.
2. Moremi N, Claus H, Mshana SE. Antimicrobial resistance pattern: a report of microbiological cultures at a tertiary hospital in Tanzania. *BMC infectious diseases*. 2016 Dec;16(1):1-7.
3. Toriki A, Zahedi M, Amirmozafari N. Type of Bacterial Isolates and Antibiotic Resistance Patterns from Clinical Specimens in Yazd, Iran. *International Journal of Medical Laboratory*. 2022 Apr 3.
4. Dumar R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of gram-negative Bacilli among the clinical isolates at BPKIHS, Dharan. *BMC Research Notes*. 2019 Dec;12:1-6.
5. Hasani A, Faezi NA, Rezaee MA, Sheykhsaran E, Darabi N, Leylabadlo HE. Determination of antimicrobial resistance patterns in bloodstream infections-isolated bacteria from a university tertiary hospital patients. *International Journal of Enteric Pathogens*. 2019 Mar 11;7(2):49-54.
6. Zerín T, Islam A, Gulnazar S, Farjana NE, Begum MA, Sadia HE. Identification and Antibiotic Susceptibility of Blood Culture Isolates from Rajshahi, Bangladesh. *Journal of Scientific Research in Medical and Biological Sciences*. 2021 May 26;2(2):1-0.
7. Deku JG, Dakorah MP, Lokpo SY, Orish VN, Ussher FA, Kpene GE, Angmorkie Eshun V, Agyei E, Attivor W, Osei-Yeboah J. The epidemiology of bloodstream infections and antimicrobial susceptibility patterns: A nine-year retrospective study at St. Dominic Hospital, Akwatia, Ghana. *Journal of tropical medicine*. 2019 Sep 19;2019.
8. Ahmed SS, Shariq A, Alsallloom AA, Babikir IH, Alhomoud BN. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. *International Journal of Health Sciences*. 2019 Mar;13(2):48.
9. Al-Zahrani J, Al Dossari K, Gabr AH, Ahmed AF, Al Shahrani SA, Al-Ghamdi S. Antimicrobial resistance patterns of Uropathogens isolated from adult women with acute uncomplicated cystitis. *BMC microbiology*. 2019 Dec;19:1-5.
10. Patel HB, Soni ST, Bhagyalaxmi A, Patel NM. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. *Journal of family medicine and primary care*. 2019 Jan;8(1):154.
11. Kalgo ZM, Amin BM, Mohammed B. Antimicrobial Susceptibility Pattern of Bacterial Pathogens Isolated from Patients with Lower Respiratory Tract Infection in Kebbi State, Nigeria.
12. Santella B, Serrettiello E, De Filippis A, Folliero V, Iervolino D, Dell'Annunziata F, Manente R, Valitutti F, Santoro E, Pagliano P, Galdiero M. Lower respiratory tract pathogens and their antimicrobial susceptibility pattern: a 5-year study. *Antibiotics*. 2021 Jul 13;10(7):851.

13. Batool S, Almaghaslah D, Alqahtani A, Almanasef M, Alasmari M, Vasudevan R, Attique S, Riaz F. Aetiology and antimicrobial susceptibility pattern of bacterial isolates in community acquired pneumonia patients at Asir region, Saudi Arabia. *International Journal of Clinical Practice*. 2021 Feb;75(2): e13667.
14. Mwakalinga LK, Temu RJ, Horumpende PG, Ngowi N, Pallangyo AJ. Bacterial Isolates and Their Antibiotic Susceptibility Pattern among Patients with Infected Wounds Admitted in Orthopaedic and Trauma Ward in Tertiary Care Hospital North-Eastern Tanzania. *Journal of Biosciences and Medicines*. 2022 Jul 1;10(7):83-96.
15. Kumari D, Mishra N, Tiwari K. Isolation of bacteria from pus samples and antibiotic sensitivity pattern in a tertiary care hospital, Lucknow.
16. Patel KK, Patel S. Bacterial isolates from infected wounds and their antibiotic susceptibility patterns: Remarks about wound infection. *Journal of Advances in Microbiology Research*. 2022;3(2):52-5.
17. Samie A, Guerrant RL, Barrett L, Bessong PO, Igumbor EO, Obi CL. Prevalence of intestinal parasitic and bacterial pathogens in diarrhoeal and non-diarrhoeal human stools from Vhembe district, South Africa. *Journal of health, population, and nutrition*. 2009 Dec;27(6):739.
18. Beyene AM, Gezachew M, Mengesha D, Yousef A, Gelaw B. Prevalence and drug resistance patterns of Gram-negative enteric bacterial pathogens from diarrheic patients in Ethiopia: A systematic review and meta-analysis. *Plos one*. 2022 Mar 16;17(3): e0265271.
19. Molla R, Tiruneh M, Abebe W, Moges F. Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. *BMC research notes*. 2019 Dec; 12:1-6.
20. Xu J, Du Q, Shu Y, Ji J, Dai C. Bacteriological profile of chronic suppurative otitis media and antibiotic susceptibility in a tertiary care hospital in Shanghai, China. *Ear, Nose & Throat Journal*. 2021 Nov;100(9):NP391-6.
21. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. *Clinical Microbiology and Infection*. 2008 Dec; 14:2-8.
22. Allegranzi B, Luzzati R, Luzzani A, Girardini F, Antozzi L, Raiteri R, Di Perri G, Concia E. Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections. *Journal of Hospital Infection*. 2002 Oct 1;52(2):136-40.
23. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. *Clinical infectious diseases*. 2001 Sep 1;33(5):615-21.
24. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. *American journal of clinical dermatology*. 2002 Feb; 3:1-7.
25. Del Arco A, Tortajada B, De La Torre J, Olalla J, Prada JL, Fernández F, Rivas F, García-Alegría J, Faus V, Montiel N. The impact of an antimicrobial stewardship programme on the use of antimicrobials and the evolution of drug resistance. *European Journal of Clinical Microbiology & Infectious Diseases*. 2015 Feb;34:247-51.
26. Lueangarun S, Leelarasamee A. Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study. *Interdisciplinary Perspectives on Infectious Diseases*. 2012 Aug 2;2012.
27. Lambraki IA, Cousins M, Graells T, Léger A, Henriksson P, Harbarth S, Troell M, Wernli D, Søgaaard Jørgensen P, Desbois AP, Carson CA. Factors influencing antimicrobial resistance in the European food system and potential leverage points for intervention: A participatory, One Health study. *Plos one*. 2022 Feb 22;17(2): e0263914.
28. Neuman MI, Kelley M, Harper MB, File Jr TM, Camargo Jr CA, EMNet Investigators. Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. *The Journal of emergency medicine*. 2007 May 1;32(4):349-57.
29. Gopal Rao G. Risk factors for the spread of antibiotic-resistant bacteria. *Drugs*. 1998 Mar;55(3):323-30.
30. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by *Pseudomonas aeruginosa*. *Microbial Drug Resistance*. 2005 Mar 1;11(1):68-74.
31. Burroughs T, Najafi M, Lemon SM, Knobler SL, editors. The resistance phenomenon in microbes and infectious disease vectors: implications for human health and strategies for containment: workshop summary.
32. Park DH, Lee CM, Chang E, Kang CK, Park WB, Kim NJ, Choe PG, Oh MD. Clinical impact of empirical antibiotic therapy in patients with coronavirus disease 2019 requiring oxygen therapy. *Journal of Korean Medical Science*. 2022 Jul 11;37(29).
33. Uchil RR, Kohli GS, KateKhaye VM, Swami OC. Strategies to combat antimicrobial resistance. *Journal of clinical and diagnostic research: JCDR*. 2014 Jul;8(7):ME01.
34. Williams JD, Sefton AM. The prevention of antibiotic resistance during treatment. *Infection*. 1999 Mar;27(Suppl 2): S29-31.

35. Wall S. Prevention of antibiotic resistance—an epidemiological scoping review to identify research categories and knowledge gaps. *Global Health Action*. 2019 Dec 13;12(sup1):1756191.
36. Caron WP, Mousa SA. Prevention strategies for antimicrobial resistance: a systematic review of the literature. *Infection and Drug Resistance*. 2010 May 21:25-33.
37. Foucault C, Brouqui P. How to fight antimicrobial resistance. *FEMS Immunology & Medical Microbiology*. 2007 Mar 1;49(2):173-83.
38. Abushaheen MA, Muzaheed, Fatani AJ, Alosaimi M, Mansy W, George M, et al. Antimicrobial resistance, mechanisms and its clinical significance. *Disease-a-Month*. 2020;66(6):100971.
39. Norman DC. Management of Antibiotic-Resistant Bacteria. *Journal of the American Geriatrics Society*. 2002 Jul; 50:242-6.
40. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J, Bielicki J, de Kraker M. Surveillance for control of antimicrobial resistance. *The Lancet Infectious Diseases*. 2018 Mar 1;18(3): e99-106.
41. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. *European Respiratory Journal*. 2011 May 1;37(5):978-81.
42. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathogens and global health*. 2015 Oct 3;109(7):309-18.
43. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, Nisar MA, Alvi RF, Aslam MA, Qamar MU, Salamat MK. Antibiotic resistance: a rundown of a global crisis. *Infection and drug resistance*. 2018; 11:1645.
44. Morrison L, Zembower TR. Antimicrobial resistance. *Gastrointestinal Endoscopy Clinics*. 2020 Oct 1;30(4):619-35.
45. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Therapeutic advances in drug safety*. 2014 Dec;5(6):229-41.